Abstract |
The Cytomegalovirus Retinitis Retreatment Trial was a multicenter clinical trial designed to evaluate three treatments for the treatment of relapsed CMV retinitis; (1) foscarnet; (2) 'high-dose' ganciclovir, and (3) combination foscarnet and ganciclovir. Two hundred seventy-nine patients were enrolled and randomly assigned to one of these three regimens. Patients were followed monthly for 6 months and every 3 months thereafter. Outcomes of interest included: (1) mortality; (2) retinitis progression; (3) change in retinal area affected by CMV; (4) loss of visual field; (5) loss of visual acuity; (6) quality of life; and (7) treatment side effects.
|
Authors | D A Jabs |
Journal | Antiviral research
(Antiviral Res)
Vol. 29
Issue 1
Pg. 69-71
(Jan 1996)
ISSN: 0166-3542 [Print] Netherlands |
PMID | 8721550
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antiviral Agents
- Foscarnet
- Ganciclovir
|
Topics |
- Acquired Immunodeficiency Syndrome
(complications, drug therapy, mortality)
- Antiviral Agents
(adverse effects, therapeutic use)
- Cytomegalovirus Retinitis
(drug therapy, mortality)
- Disease Progression
- Drug Therapy, Combination
- Foscarnet
(administration & dosage, adverse effects, therapeutic use)
- Ganciclovir
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Multicenter Studies as Topic
- Randomized Controlled Trials as Topic
- Research Design
|